Thursday, Guardant Health, Inc. (GH) announced a multi-year strategic collaboration with Nuvalent, Inc. (NUVL) to support the development and potential commercialization of the latter's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.
Under the partnership, the companies will utilize Guardant's portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies.
They will also evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics to support potential regulatory approvals of Nuvalent's current investigational candidates.
Further, the companies will collaborate on the global commercialization of Nuvalent's product candidates, if approved, and Guardant companion diagnostics across major global key markets.
Currently, GH is trading at $84.36, up 1.14 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.